Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.50 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788799 | 0.89 | LMNA (0.62) | ALDH1A1LMNAHRH4ESPL1HTT | |
| SCHEMBL561582 | 0.80 | ALDH1A1 (0.52) | ALDH1A1LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL30370886 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNAESPL1HTTSMN1; SMN2 | |
| SCHEMBL1457195 | 0.80 | ALDH1A1 (1.00) | ALDH1A1LMNAESPL1HTTSMN1; SMN2 | |
| SCHEMBL10233503 | 0.79 | MEN1 (0.54) | ALDH1A1LMNAHRH4ESPL1HTT | |
| SCHEMBL2788826 | 0.79 | ALDH1A1 (0.70) | ALDH1A1LMNAESPL1HTTSMN1; SMN2 | |
| SCHEMBL18398253 | 0.78 | G6PD (0.56) | ALDH1A1LMNAHRH4HTTSMN1; SMN2 | |
| SCHEMBL20484476 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNAHRH4HTTSMN1; SMN2 | |
| SCHEMBL2789413 | 0.78 | LMNA (0.47) | ALDH1A1LMNAHRH4ESPL1HTT | |
| SCHEMBL8913002 | 0.77 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| WO-2018187652-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | WO | disclosed |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | US | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | ALDH1A1 899/4885LMNA 4278/4885HRH4 213/4885 |
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | HRH4, HRH3, HRH2 | ALDH1A1 1641/4885LMNA 4837/4885HRH4 1/4885 |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | HRH4, HRH3, HRH2 | ALDH1A1 1641/4885LMNA 4837/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.